Medical Oncologists’ Perceptions of Newly Launched Perjeta are Very Promising, Despite Initial Concerns of Increased Cost Associated with Combining Two Premium-Priced Monoclonal Antibodies to Treat HER2-Positive Breast Cancer
09:30 EDT 5 Sep 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
BioTrends Research Group, one of the world’s leading research and
advisory firms for specialized biopharmaceutical issues, finds that
Roche/Genentech’s Perjeta (pertuzumab) which has been available in the
U.S. for one month ...
Other Sources for this Article
BioTrends Research Group, LLC
Dan Winkelman, 610-321-9438
dwinkelman@bio-trends.com
or
Decision
Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
More From BioPortfolio on "Medical Oncologists’ Perceptions of Newly Launched Perjeta are Very Promising, Despite Initial Concerns of Increased Cost Associated with Combining Two Premium-Priced Monoclonal Antibodies to Treat HER2-Positive Breast Cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
